Physician profile
Juan Guzman-Negron
NPI 1013222959
$18,588.67
in general payments reported to CMS, 2019-2025
18 companies · $1,880 in 2025
The $1,880 reported for 2025 was more than what a typical Urogynecology and Reconstructive Pelvic Surgery (Urology) provider received nationally (typical 2025 total: $782).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $631 · 2020: $469 · 2021: $1,186 · 2022: $13K · 2023: $129 · 2024: $871 · 2025: $1,880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,458 · Food and Beverage: $1,422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,458.15 |
| Food and Beverage | $1,421.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $13,190.71 | 2021-2025 | Interstim |
| Procept Biorobotics Corporation | $1,798.48 | 2021-2025 | |
| Teleflex LLC | $764.34 | 2022-2024 | Urolift |
| Boston Scientific Corporation | $539.66 | 2019-2024 | |
| Medtronic USA, INC. | $513.96 | 2019-2020 | |
| Axonics, INC. | $423.84 | 2021 | |
| Rochester Medical Corporation | $423.29 | 2020-2021 | |
| Astellas Pharma US INC | $283.61 | 2019-2021 | |
| Olympus Latin America, INC. | $160.31 | 2024 | Bovie |
| Merck Sharp & Dohme LLC | $124.26 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $100.00 | 2024 | Opdivo |
| C. R. Bard, INC. & Subsidiaries | $79.43 | 2021 | |
| Janssen Pharmaceuticals, INC | $47.40 | 2025 | Erleada, Akeega |
| Tolmar, INC. | $41.61 | 2024-2025 | Jatenzo, Eligard |
| Coloplast Corp | $30.35 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $25.71 | 2019 | |
| Abbvie INC. | $25.00 | 2024 | |
| Olympus America INC. | $16.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Guzman-Negron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.